NEO New Oncology AG, a Cologne based cancer diagnostics company, today announced the closing of a financing round with a total investment of app. EUR 5 Million.
“I am pleased by the strong interest that NEO New Oncology AG has received from the investment community,” commented Dr Andreas Jenne, CEO of NEO New Oncology AG. “Together with the proceeds from the first closing earlier this year, the funds will help us to make NEOliquid, a genomic diagnostics test that identifies all therapeutically actionable genome alterations from a simple blood sample, available to patients even faster.”
- Curetis licenses Acumen’s proprietary sepsis biomarker panel for use with Unyvero Platform
- Diagnostics Development (DxD) Hub in Singapore to support Acumen in development and clinical validation of the panel
- Acumen to distribute Unyvero product line in ASEAN countries
Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that it has obtained a world-wide, non-exclusive license to AcuSept, a proprietary biomarker panel from Acumen Research Laboratories Pte Ltd. (Singapore). The panel is in advanced clinical development and will be used by Curetis and Acumen for the joint development and clinical validation of a sepsis host response test on the Unyvero Platform. Acumen’s activities in Singapore will be supported by NUS Enterprise and the Diagnostics Development (DxD) Hub, a national initiative led by the Agency for Science, Technology and Research (A*STAR), which aims to accelerate diagnostics innovations into market-ready products. » Read more...